Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

Urinary Bladder

Urinary Bladder

The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Physiology of Urine Formation

Physiology of Urine Formation

Urine formation is an essential function of the human body. It plays a critical role in maintaining homeostasis by regulating the volume and composition of body fluids. The kidneys, the primary organs involved in this process, filter blood to remove waste products and excess substances, ultimately producing urine.
Glomerular Filtration
The first stage in urine formation is glomerular filtration. Each kidney contains approximately 1 million nephrons, the functional units of filtration, with a...

Physiology of the Genitourinary System II: Tubular Reabsorption and Secretion

Physiology of the Genitourinary System II: Tubular Reabsorption and Secretion

The kidneys maintain homeostasis through filtration, reabsorption, and secretion. Tubular reabsorption and secretion are crucial in forming urine and regulating electrolytes, water balance, and waste elimination.Tubular Reabsorption and Secretion ProcessesTubular reabsorption is the process that reclaims essential substances such as electrolytes, glucose, amino acids, and water from the glomerular filtrate back into the bloodstream. This is achieved through passive and active transport...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The female urethra: urethral function throughout a woman's lifetime.

International urogynecology journal·2023

Same author

A prospective, randomized trial comparing intravesical dimethyl sulfoxide (DMSO) to bupivacaine, triamcinolone, and heparin (BTH), for newly diagnosed interstitial cystitis/painful bladder syndrome (IC/PBS).

Neurourology and urodynamics·2023

Same author

Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study.

Urology·2021

Same author

Vaginal calculus in a patient with a mid-urethral sling mesh exposure.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2020

Same author

Nocturia: A Highly Prevalent Disorder With Multifaceted Consequences.

Urology·2019

Same author

Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence.

The Journal of urology·2019

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

The evolution of transdermal therapy for overactive bladder.

¹Evanston Continence Center, North Shore University Health System, University of Chicago, Pritzker School of Medicine, 1000 Central Street, Suite 730, Evanston, IL 60201, USA. psand@northshore.org

Current Urology Reports

|August 28, 2009

Summary

Oxybutynin chloride, an overactive bladder treatment, evolved through delivery systems. Transdermal oxybutynin gel offers improved efficacy and tolerability with minimal side effects.

More Related Videos

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

Related Experiment Videos

Last Updated: Jun 20, 2026

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

Area of Science:

Pharmacology
Urology
Drug Delivery Systems

Background:

Oxybutynin chloride has been a mainstay for overactive bladder (OAB) treatment for over 30 years.
Traditional oral formulations face challenges with tolerability due to antimuscarinic side effects.
Advancements in delivery systems aim to enhance efficacy and patient compliance.

Purpose of the Study:

To review the evolution of oxybutynin chloride delivery systems.
To highlight the benefits of transdermal delivery in improving tolerability and maintaining efficacy.
To discuss the latest advancements, including transdermal oxybutynin gel.

Main Methods:

Review of existing literature on oxybutynin chloride formulations.
Comparison of efficacy and tolerability profiles across different delivery methods.
Analysis of pharmacokinetic data and side effect profiles.

Main Results:

Early delivery systems (intravesical, suppositories) improved tolerability by reducing first-pass metabolism.
Extended-release oral formulations offered better tolerability than immediate-release versions.
Transdermal delivery significantly reduced systemic side effects, such as dry mouth (7%) and constipation.
A novel transdermal oxybutynin gel further minimized application site reactions while preserving efficacy.

Conclusions:

Transdermal delivery represents a significant advancement in oxybutynin chloride therapy for OAB.
The transdermal oxybutynin gel formulation demonstrates a favorable balance of efficacy and improved tolerability.
Further research into optimized transdermal systems may enhance OAB management.